[an error occurred while processing this directive]
|CANCER & TREATMENTS FOR CANCER CENTER PATIENTS PREVENTION & RISK ASSESSMENT CLINICAL TRIALS & RESEARCH LIVING WITH CANCER|
Please note: This article is part of the Cancer Center's News Archive and is here for historical purposes. The information and links may no longer be up-to-date.
Michigan Oncology Journal Summer 2000
The primary objective of the Selenium and Vitamin E Chemoprevention Trial (SELECT) is to assess the effect of selenium and vitamin E (alone and in combination) on the reduction of prostate cancer incidence. This trial is a Phase III, double-blind, placebo-controlled, 2 x 2 factorial study of selenium and vitamin E (alone and in combination) in 32,400 healthy men ages 55 and older (or age 50 and older for African American men). Study duration will be 12 years, with a five-year uniform accrual period and a minimum of seven years of treatment. Participants will receive study medication until the end of the trial. Therefore, study treatment will be between seven and 12 years, depending upon when the participant was randomized. Contact Cancer AnswerLine™ 800-865-1125.
The U-M Nicotine Research Laboratory is currently recruiting women who want to quit smoking and who have a history of depression. We are seeking women ages 20 to 65. They must be regular smokers (10 or more cigarettes per day for at least three years), and they must be looking for a smoking cessation program. The study examines the role of depression in smoking cessation. The 14-week program involves one-on-one counseling, a few blood samples, nicotine-replacement patches, administration of an antidepressant or placebo, and collection of saliva samples. Participants who complete the study will receive $180. We are located near Briarwood Mall in Ann Arbor. Free parking and childcare are available. We will work around participants' schedules. Contact Cancer AnswerLine™ 800-865-1125.
Patients with advanced malignancies and hepatic dysfunction are often denied participation in clinical trials with cytotoxic therapies. A randomized, crossover study of oral and intravenous Navelbine in patients with varying degrees of hepatic function is now being conducted at the U-M Cancer Center. This study is available for patients with malignant solid tumors and liver metastasis that are refractory to standard therapy or for which no standard therapy exists. This study is designed to include patients who have mild to severe hepatic dysfunction as evidenced by elevations in total bilirubin levels. If you are currently seeing patients whom you believe might be interested in this study, we would be happy to discuss additional eligibility criteria and study specifics with you. Contact Cancer AnswerLine™ 800-865-1125.
The Palliative Care Project is a Phase III multi-institutional, randomized study for patients with advanced cancer who are receiving palliative chemotherapy or radiation therapy. Specific metastatic diseases include breast, prostate, lung, colorectal, pancreatic, melanoma and bladder cancer. The Palliative Care Program combines standard medical care and supportive care from hospice nurses and social workers to provide a transitionless model of care to patients. Typically, patients are not enrolled into a hospice program until all treatments have been used. The purpose of this study is to investigate the value in enrolling patients into a supportive program early, while they are receiving therapy for their disease and to continue to follow patients from active treatment to supportive care, including bereavement. Patients will be enrolled into a Phase III study with randomization to the palliative-care arm or the conventional-care arm. Quality of life for the patient and the family, health outcomes and cost effectiveness will be evaluated in both groups. Enrollment into the Palliative Care Project will not alter the type of treatment that patients receive while being followed on this study. For more information, contact Cancer AnswerLine™ 800-865-1125.
Although the procedure has been available at the University of Michigan for a number of years, the Endoscopic Ultrasound (EUS) Program has been created to facilitate referrals for the procedure. EUS is of great value in the diagnosis and management of patients with suspected and/or known esophageal, gastric, pancreatic, biliary, mediastinal and rectal tumors. EUS provides improved diagnostic and staging information that can be used in innovative cancer treatment protocols within the institution or at the referring physician's center. For further information, contact Cancer AnswerLine™ 800-865-1125.
Lung Cancer Symposium
The Cancer Center's Field of Dreams Symposium: New Frontiers in Lung Cancer will be held on Saturday, October 7 at the Towsley Center. Guest speakers will include David Johnson, M.D., Vanderbilt University, and John Minna, M.D., from UT Southwestern. Topics will include screening, chemoprevention, new imaging modalities and state-of-the-art therapy for non-small cell and small cell lung cancer. Contact Cancer AnswerLine™ 800-865-1125.
|[an error occurred while processing this directive]|